Duration of Antibiotic Treatment in Community-Acquired Pneumonia-Reference-Cited by-同舟云学术

Duration of Antibiotic Treatment in Community-Acquired Pneumonia

Published:2016-09-01 Issue:9 Volume:176 Page:1257
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Uranga Ane¹,España Pedro P.¹,Bilbao Amaia²,Quintana Jose María³,Arriaga Ignacio⁴,Intxausti Maider⁴,Lobo Jose Luis⁵,Tomás Laura⁵,Camino Jesus⁶,Nuñez Juan⁶,Capelastegui Alberto¹

Affiliation:

1. Department of Pneumology, Galdakao-Usansolo Hospital, Galdakao, Bizkaia, Spain

2. Research Unit, Basurto University Hospital, Bilbao, Bizkaia, Spain

3. Research Unit, Galdakao-Usansolo Hospital, Galdakao, Bizkaia, Spain

4. Department of Pneumology, Basurto University Hospital, Bilbao, Bizkaia, Spain

5. Department of Pneumology, Alava University Hospital, Vitoria, Alava, Spain

6. Department of Pneumology, San Eloy Hospital, Barakaldo, Bizkaia, Spain

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Cited by 226 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving Antibiotic Prescribing for Children with Community-acquired Pneumonia in Outpatient Settings;The Journal of Pediatrics;2024-11

2. Oral versus intravenous empirical antibiotics in children and adolescents with uncomplicated bone and joint infections: a nationwide, randomised, controlled, non-inferiority trial in Denmark;The Lancet Child & Adolescent Health;2024-09

3. Real Life Experience in Short Treatments for Community-Acquired Pneumonia: An Observational Propensity Cohort Study;Archivos de Bronconeumología;2024-09

4. Biomarker guided antibiotic stewardship in community acquired pneumonia: A randomized controlled trial;PLOS ONE;2024-08-20

5. An investigation of broad-spectrum antibiotic-induced liver injury based on the FDA Adverse Event Reporting System and retrospective observational study;Scientific Reports;2024-08-06